Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd are preparing to enter the fast-growing market for Semaglutide — a blockbuster drug used to treat Type 2 Diabetes Mellitus and Obesity. While Zydus is gearing up to launch a differentiated formulation in India and later expand to Brazil and Canada, Torrent has begun regulatory filings in Brazil positioning itself among the first wave of generic entrants once patent protections for the molecule expires next year.

The Torrent-management disclosed that regulatory filings for 65 molecules are awaiting approval from Brazil’s drug-regulatory authority, ANVISA (Agência Nacional de Vigilância Sanitária). Among these is Semaglutide, for which Torrent’s application is already under review. “I can confirm that our application is filed with AN

See Full Page